- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05258526
Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study) (BENEFIT-CA)
Home Based Exercise for Patients With Breast or Prostate Cancer During Treatment: a Feasibility Trial (The BENEFIT-CA Study)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This feasibility trial aims to assess a home-based exercise program, including a 3-month intervention of structured physical activity and health education for individuals with breast or prostate cancer. The main objective of this trial is to assess the adherence of cancer patients to a program of structured exercise, mixed with a health education approach, implemented and accompanied in a remote approach.
The data collection will include variables related to: (a) recruitment and retentions rates; (b) attendance to exercise sessions; (c) fatigue and quality of life levels; (d) functional capacity levels; (e) adverse events related or not to the study; (f) patient selected outcomes.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Daniel Umpierre de Moraes, PhD
- Telefoonnummer: 555133596332
- E-mail: danielumpierre@hcpa.edu.br
Studie Contact Back-up
- Naam: Larissa Xavier Neves da Silva, Master
- Telefoonnummer: 555133596332
- E-mail: larissaxns@gmail.com
Studie Locaties
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazilië, 90035-007
- Werving
- Hospital de Clinicas de Porto Alegre
-
Contact:
- Daniel Umpierre de Moraes, PhD
- Telefoonnummer: 555133596332
- E-mail: danielumpierre@hcpa.edu.br
-
Contact:
- Larissa Xavier Neves da Silva, MSc
- Telefoonnummer: 555133596332
- E-mail: larissaxns@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- eighteen years old minimum;
- be living in Porto Alegre or metropolitan region;
- breast cancer stage 0 - III OR
- localized prostate cancer;
- undergoing hormonal treatment / manipulation in isolation or combined with other therapies three months prior to the entrance in the study;
- hormonal therapy / manipulation planned to be active throughout the study duration;
- not engaged in any exercise training for more than once a week for the past 6 months;
- in case of previous surgical procedure, the patient must have medical clearance at the moment of the contact to begin the study or be cleared to do so in the near future (up to two weeks).
Exclusion Criteria:
- metastatic phase / progression of the disease or active regional location prior to beginning of the study;
- inability to understand the terms and conditions of study due to language, hearing, cognitive or severe psychiatric issues;
- another family member, who lives at the same residence, participating in the study;
- planning to move or major absence (more than two weeks) during the study;
- history of cardiovascular disease (except controlled hypertension) or severe cardiopulmonary disease, as well as history of heart attack, revascularization procedures, profound venous thrombosis, encephalic vascular accident (brain stroke) or pulmonary embolism in the past twelve months;
- chronic pulmonary disease that requires oxygen or corticosteroid therapy;
- kidney disease with or that is going to begin the use of dialysis or waiting for a kidney transplant;
- severe nausea, anorexia or any other condition which does not allow to perform physical exercise;
- medical contraindication to exercise training.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Home-based exercise program
This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
|
The intervention will be based on a remote approach, lasting 12 weeks.
The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week.
The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Trial adherence
Tijdsspanne: Up to12 weeks.
|
Proportion of self-reported exercise episodes (out of 36 episodes, total) during the study.
|
Up to12 weeks.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recruitment yields
Tijdsspanne: Up to 8 weeks before allocation to the study intervention.
|
Proportion of included participants (who signed the informed consent) in relation to the total number of screened individuals for eligibility.
|
Up to 8 weeks before allocation to the study intervention.
|
|
Adverse events throughout the study
Tijdsspanne: Up to 12 weeks.
|
Self-reported adverse events, related or not to the study.
These measures will be mostly received by phone calls or text messaging.
|
Up to 12 weeks.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Fatigue levels at baseline and at the end of the study
Tijdsspanne: Baseline; Week 12.
|
Fatigue scores using specific questionnaires of Functional Assessment of Cancer Therapy (FACT questionnaire) for breast or prostate cancer patients.
|
Baseline; Week 12.
|
|
Quality of life, based on the Functional Assessment of Cancer Therapy (FACT questionnaire)
Tijdsspanne: Baseline; Week 12.
|
Quality of life scores using specific questionnaires of FACT (Functional Assessment of Cancer Therapy) for breast or prostate cancer patients.
|
Baseline; Week 12.
|
|
Walking capacity
Tijdsspanne: Baseline; Week 12.
|
Total distance (in meters) performed during the six minute walk test.
|
Baseline; Week 12.
|
|
Handgrip strength
Tijdsspanne: Baseline; Week 12.
|
Maximum strength (in kgf) achieved by both hands in a handgrip test using a hand dynamometer.
|
Baseline; Week 12.
|
|
Abdominal circumference
Tijdsspanne: Baseline; Week 12.
|
Anthropometric measure of the highest abdominal circumference, using a metallic measuring tape.
|
Baseline; Week 12.
|
|
Physical activity levels
Tijdsspanne: Single assessment at baseline.
|
Physical activity calculated in minutes and intensity per week, of physical activity using the International Physical Activity Questionnaire (IPAQ).
|
Single assessment at baseline.
|
|
Patient selected outcomes
Tijdsspanne: Week 12.
|
Through the development of the study, participants will be asked to engage in a focal group to discuss outcomes relevant to be assessed in trials with exercise interventions targeted for patients with breast or prostate cancer.
|
Week 12.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Daniel Umpierre de Moraes, PhD, Hospital de Clinicas de Porto Alegre
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2021-0262
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Files will be as de-identified as possible before public data sharing. After data protection and data handling routines, de-identified data will be readily available to all project contributors. We consider research data gathered from data collection from research participants pertains primarily to these individuals. Therefore, all individual data will be available to their owners throughout the project. Structured data that will result from this research project will pertain to the PI (Daniel Umpierre), who will be responsible for data integrity, and to the institution (Hospital de Clinicas de Porto Alegre).
The specific structure for data sharing as well as plataforms are still to be defined. As soon, we define the remaining details of our data sharing strategy the IPD plan will be updated.
IPD-tijdsbestek voor delen
Due to space and management constraints, we are planning:
- To retain and store project documentation (informed consents, IRB communication, subjects' communication) for at least 10 years after the study completion (anticipated time: up to 2033).
- To retain and share project resources (instruments, intervention materials) as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.
- To retain and share datasets as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- Leerprotocool
- Formulier voor geïnformeerde toestemming (ICF)
- Klinisch onderzoeksrapport (CSR)
- Analytische code
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .